For platelet control as individual as you
|
|
- Sharleen Grant
- 5 years ago
- Views:
Transcription
1 For platelet control as individual as you Explore the possibilities of Immune Thrombocytopenic Purpura (ITP) treatment. Important Risk Information WARNING: INTRAVASCULAR HEMOLYSIS (IVH) Intravascular hemolysis (IVH) leading to death has been reported in patients treated for immune thrombocytopenic purpura (ITP) with WinRho SDF. IVH can lead to clinically compromising anemia and multi-system organ failure including acute respiratory distress syndrome (ARDS). Serious complications including severe anemia, acute renal insufficiency, renal failure and disseminated intravascular coagulation (DIC) have also been reported. Closely monitor patients treated with WinRho SDF for ITP in a healthcare setting for at least eight hours after administration. Perform a dipstick urinalysis to monitor for hematuria and hemoglobinuria at baseline and then after administration at 2 hours, 4 hours and prior to the end of the monitoring period. Alert patients and monitor the signs and symptoms of IVH including back pain, shaking chills, fever, and discolored urine or hematuria. Absence of these signs and/or symptoms of IVH within eight hours do not indicate IVH cannot occur subsequently. If signs and/or symptoms of IVH are present or suspected after WinRho SDF administration, post-treatment laboratory tests should be performed including plasma hemoglobin, haptoglobin, LDH, and plasma bilirubin (direct and indirect).
2 If you re living with ITP, WinRho SDF may be right for you. What is WinRho SDF? WinRho SDF is a protein product, called an immune globulin, which is made from human plasma. 1 WinRho SDF is used to increase the number of platelets in the blood of Rh-positive individuals who have a bleeding disorder called immune thrombocytopenic purpura (ITP). 1 A normal platelet count is usually higher than 150,000/mm 3. 2 Hi, I m Rose. I was diagnosed with ITP about a year ago, and after trying other options, I turned to WinRho SDF. Read my story on page 8. Living with ITP can be challenging ITP results in an abnormally low number of platelets. Platelets are needed for your blood to clot properly. If your blood doesn t clot properly, there is an increased risk for bruising and bleeding. 1 WinRho SDF is a type of therapy that has been used to treat ITP for nearly 20 years. For most people, living with ITP means making lifestyle changes. You probably had to either change or stop some of the things you enjoy doing. In some people, ITP can go away in a few months. Others may have it for a year or longer. This is a summary of the important information you need to know about treatment for your Immune Thrombocytopenic Purpura (ITP) with WinRho SDF. It does not take the place of talking with your doctor and does not contain all of the information available about WinRho SDF. If you have any questions after reading this information, make sure you ask your doctor or nurse. What is the most important information I should know about WinRho SDF? Some patients taking WinRho SDF for immune thrombocytopenic purpura (ITP) have had severe, life threatening bleeding and clotting problems. For this reason, you need to remain under observation for at least 8 hours following each treatment with WinRho SDF and your doctor will ask you to take blood and urine tests before and after infusion with WinRho SDF. Take the ITP treatment self-assessment at Share results with your doctor and discuss WinRho SDF 2
3 WinRho SDF may be an effective, convenient treatment for you When steroids don t work, there are other effective treatment options. WinRho SDF works quickly. Platelet counts generally rise within 1 to 2 days and usually stay up for 30 days. 1 In some clinical trials, platelet counts were raised for up to 90 days. 3 WinRho SDF is convenient. 3 to 5 minutes to receive an entire dose of WinRho SDF - Some doctors may prefer to administer the dose over longer periods of time, such as 30 minutes. 8-hour monitoring period in a healthcare setting after it is given you are able to move around as you like 1 WinRho SDF offers individualized dosing. Dosing is based on your individual response to the medicine. - For example, you may receive WinRho SDF every month, or every few months. To receive WinRho SDF, you must have a spleen and an Rh-positive blood type. 1 WinRho SDF is well tolerated. Patients taking WinRho SDF have few side effects, and doctors have been using WinRho SDF for nearly 20 years to treat ITP. 1 Hello, my name is Brian. A f ter 7 years, my platelets were still stable with WinRho SDF. Want to know more about my experience? Go to page 7. Some patients taking WinRho SDF have had problems with their kidneys and other organs. Problems usually occur within 4 to 8 hours after getting an infusion. Tell your doctor or healthcare provider right away if you have any of the following signs or symptoms after getting a WinRho SDF infusion: back pain shaking chills fever dark or oddly colored urine decreased urination swelling or sudden weight gain shortness of breath rash dizziness The faster you gain control of your platelets, and the longer they stay at healthy levels, the less limiting your ITP may be. Take the ITP treatment self-assessment at Share results with your doctor and discuss WinRho SDF 4
4 WinRho SDF is proven effective in clinical trials In clinical studies, of people experienced a successful rise in their platelet levels. 1* WinRho SDF is designed to help protect platelets When you have ITP, your body destroys healthy platelets. WinRho SDF is recommended as a 1 st -line treatment by the American Society of Hematology (ASH). ASH looked at different ways to treat ITP and included WinRho SDF (anti-d immunoglobulin) as a 1 st -line option, as well as steroids and IVIg. 4 YEARS OF CLINICAL EXPERIENCE WinRho SDF is an anti-d medicine that contains a high number of antibodies that attach to red blood cells (RBCs). WinRho SDF is thought to protect the platelets of Rh-positive people by coating their RBCs. - As a result, the coated RBCs are destroyed instead of the platelets. - This leads to an increased number of platelets in the blood and fewer symptoms of ITP. Who should not use WinRho SDF? You should not use WinRho SDF for any treatment if you: have ever had a severe allergic reaction (such as trouble breathing, hives, passing out) after getting any blood product or blood product transfusion. have an immune globulin A (IgA) deficiency. - The way that WinRho SDF works is not fully understood. 1 Your main goal is to increase your platelets quickly, and keep them up for as long as possible. WinRho SDF may help you do just that. Take the ITP treatment self-assessment at Share results with your doctor and discuss WinRho SDF * Studies of non-splenectomized (spleen not removed), Rho(D)-positive patients included 24 children with chronic ITP, 146 children with acute ITP, 24 adults with chronic ITP, and 11 children and 52 adults with ITP caused by HIV infection. For more detail on the studies and results, see the back cover. 6
5 Brian stopped responding to prednisone and IVIg Brian s doctor started him on prednisone, but he stopped responding after 1 week. Over the next 5 months, Brian tried increasing doses of IVIg, but his platelets only increased to a maximum of 50,000/mm 3, and then dropped to 5,000/mm 3. Then, Brian switched to WinRho SDF Results: Within a week of trying WinRho SDF, Brian s platelet count went up to 295,000/mm 3. Status: After 7 years, Brian received monthly doses of WinRho SDF, and his platelets stayed at a safe level with no active bleeding. Real WinRho SDF results for Brian* Age: 54 years 3 Weight: 142 lb Baseline platelet count: 37,000/mm 3 Hemoglobin: 16.5 g/dl Symptoms: Bruising and diffuse petechiae (round spots that are a result of bleeding under the skin) Initial ITP therapies: Prednisone, IVIg * Brian is based on an actual patient treated with WinRho SDF as a maintenance therapy for chronic ITP. Patient responses to individual treatment options may vary. A normal platelet count is usually higher than 150,000/mm 3. 2 You should not use WinRho SDF for treatment of ITP if you: have Rh-negative blood. have had your spleen removed. have a problem called autoimmune hemolytic anemia. have other preexisting bleeding problems. 8
6 Rose s ITP wasn t controlled with prednisone, IVIg, or rituximab After trying different therapies for her chronic ITP for over a year, Rose and her doctor turned to WinRho SDF. Then, Rose switched to WinRho SDF Results: Rose s doctor transitioned her to WinRho SDF as a maintenance therapy. With its individualized maintenance dosing, Rose s doctor was able to monitor her platelet count and administer infusions based on her platelet response. Status: After receiving periodic doses of WinRho SDF, Rose s chronic ITP was stabilized. Real WinRho SDF results for Rose* Age: 26 years 3 Weight: 132 lb Baseline platelet count: 5,000/mm 3 Hemoglobin: 13.9 g/dl Symptoms: Petechiae (round spots that are a result of bleeding under the skin) and oral blood blisters Initial ITP therapies: Prednisone, IVIg, rituximab * Rose is based on an actual patient treated with WinRho SDF as a maintenance therapy for chronic ITP. Patient responses to individual treatment options may vary. A normal platelet count is usually higher than 150,000/mm 3. 2 Rituximab is not FDA-approved for ITP indication. What should I avoid while using WinRho SDF? WinRho SDF may interfere with your immune response to routine immunizations. Tell your doctor if you have recently been vaccinated or are planning to be vaccinated. WinRho SDF can interfere with certain blood tests. It is important to tell the person taking your blood and the doctor that you got WinRho SDF. 10
7 On IVIg, Lori kept having ITP symptoms When her ITP persisted, Lori needed a treatment that would help her sustain a healthy platelet level. Then, Lori switched to WinRho SDF Results: Lori s doctor chose to initiate WinRho SDF at an individualized dose that was based on her personal profile and goals. After her first dose, Lori s platelet count increased to 74,000/mm 3 after 48 hours. Thankfully, she didn t have the severe headaches she experienced with IVIg. Status: Following her first treatment, Lori s platelets remained at a healthy level for 6 weeks, after which she went to an infusion center to receive her next dose of WinRho SDF. Her doctor planned to give her additional WinRho SDF doses in the future. Real WinRho SDF results for Lori* Age: 13 years 3 Weight: 119 lb Baseline platelet count: 2,000/mm 3 Hemoglobin: 10 g/dl Symptoms: Menorrhagia (heavy periods) and diffuse petechiae, which are round spots that are a result of bleeding under the skin. Initial ITP therapies: Corticosteroids, IVIg * Lori is based on an actual pediatric patient treated with WinRho SDF as a maintenance therapy for chronic ITP. Patient responses to individual treatment options may vary. A normal platelet count is usually higher than 150,000/mm 3. 2 What are the possible or reasonably likely side effects of WinRho SDF? The most common side effects of WinRho SDF are headache chills fever weakness diarrhea nausea and vomiting achy muscles feeling light-headed or dizziness fainting flushing rash sweating 12
8 WinRho SDF is generally well tolerated The safety and tolerability profile of WinRho SDF has been proven in many patients. Like most medicines, WinRho SDF is not free of side effects. They usually occur within 4 to 8 hours after receiving an infusion. If you experience any of these symptoms, talk with your doctor right away: back pain, shaking, chills, fever, dark or oddly colored urine, decreased urination, swelling or sudden weight gain, shortness of breath, rash, and/or dizziness. 1 Continue monitoring for these signs and symptoms for 72 hours after each treatment with WinRho SDF. 1 To help ensure your well-being, there is an 8-hour monitoring period in a healthcare setting after WinRho SDF is given. You can move around as you like during the monitoring period. 1 Tell your doctor right away if you have: Take the ITP treatment self-assessment at Share results with your doctor and discuss WinRho SDF a fever over 100 F shaking or chills that continue or get worse a painful lump or swelling (because this may be a sign of a blood clot) bruising that is increasing in diameter (because this may be a sign of a clotting problem) oddly colored urine trouble urinating severe back pain severe abdominal pain swelling, especially around the ankles hives shortness of breath 14
9 Cover these points about WinRho SDF with your doctor The quick infusion time of 3 to 5 minutes (unless the doctor wants to infuse for a longer period of time, such as 30 minutes). The ability for platelet levels to double in as little as 24 hours. The potential for platelet counts to be increased for 30 to 90 days. The 8-hour mobile monitoring period, in which you are able to move around as you like in the healthcare setting. Tips for talking with your doctor about WinRho SDF When it comes to managing ITP, you and your doctor are a team, working together to figure out the best treatment for you. Be your own advocate. If you think WinRho SDF may be the best option for you, talk to your doctor about it. What other information do I need to know about WinRho SDF? WinRho SDF is made from human plasma. Donors are carefully screened and the plasma is carefully cleaned, but it does have a very small risk of giving you viruses from the donor. Talk to your doctor if you have any symptoms that concern you. Take the ITP treatment self-assessment at Share results with your doctor and discuss WinRho SDF 16
10 Important Risk Information WARNING: INTRAVASCULAR HEMOLYSIS (IVH) Intravascular hemolysis (IVH) leading to death has been reported in patients treated for immune thrombocytopenic purpura (ITP) with WinRho SDF. IVH can lead to clinically compromising anemia and multi-system organ failure including acute respiratory distress syndrome (ARDS). Serious complications including severe anemia, acute renal insufficiency, renal failure and disseminated intravascular coagulation (DIC) have also been reported. Closely monitor patients treated with WinRho SDF for ITP in a healthcare setting for at least eight hours after administration. Perform a dipstick urinalysis to monitor for hematuria and hemoglobinuria at baseline and then after administration at 2 hours, 4 hours and prior to the end of the monitoring period. Alert patients and monitor the signs and symptoms of IVH including back pain, shaking chills, fever, and discolored urine or hematuria. Absence of these signs and/or symptoms of IVH within eight hours do not indicate IVH cannot occur subsequently. If signs and/or symptoms of IVH are present or suspected after WinRho SDF administration, posttreatment laboratory tests should be performed including plasma hemoglobin, haptoglobin, LDH, and plasma bilirubin (direct and indirect). Indication and important information for people being treated with WinRho SDF What is WinRho SDF? WinRho SDF is a protein product, called an immune globulin, which is made from human plasma. WinRho SDF is used to increase the number of platelets in the blood of Rh-positive individuals who have a bleeding disorder called immune thrombocytopenic purpura (ITP), which results in an abnormally low number of platelets. Platelets are needed for your blood to clot properly. If your blood doesn t clot properly, there is an increased risk for bruising and bleeding. This is a summary of the important information you need to know about treatment for your Immune Thrombocytopenic Purpura (ITP) with WinRho SDF. It does not take the place of talking with your doctor and does not contain all of the information available about WinRho SDF. If you have any questions after reading this information, make sure you ask your doctor or nurse. 1. What is the most important information I should know about WinRho SDF? Some patients taking WinRho SDF for immune thrombocytopenic purpura (ITP) have had severe, life threatening bleeding and clotting problems. For this reason, you need to remain under observation for at least 8 hours following each treatment with WinRho SDF and your doctor will ask you to take blood and urine tests before and after infusion with WinRho SDF. Some patients taking WinRho SDF have had problems with their kidneys and other organs. Problems usually occur within 4 to 8 hours after getting an infusion. Tell your doctor or healthcare provider right away if you have any of the following signs or symptoms after getting a WinRho SDF infusion: Continue monitoring for these signs and symptoms for 72 hours after each treatment with WinRho SDF. back pain shaking chills fever dark or oddly colored urine decreased urination swelling or sudden weight gain shortness of breath rash dizziness WinRho SDF contains maltose, which can give false readings on some glucose testing meters. If you are diabetic, ask your doctor what types of glucose testing meters can be used safely while you are getting WinRho SDF. 2. Who should not use WinRho SDF? You should not use WinRho SDF for any treatment if you: have ever had a severe allergic reaction (such as trouble breathing, hives, passing out) after getting any blood product or blood product transfusion. have an immune globulin A (IgA) deficiency. You should not use WinRho SDF for treatment of ITP if you: have Rh-negative blood. have had your spleen removed. have a problem called autoimmune hemolytic anemia. have other pre-existing bleeding problems. 3. What should I avoid while using WinRho SDF? WinRho SDF may interfere with your immune response to routine immunizations. Tell your doctor if you have recently been vaccinated or are planning to be vaccinated. WinRho SDF can interfere with certain blood tests. It is important to tell the person taking your blood and the doctor that you got WinRho SDF. 18 Please see full Prescribing Information at Please see full Prescribing Information at
11 4. What are the possible or reasonably likely side effects of WinRho SDF? The most common side effects of WinRho SDF are headache achy muscles chills feeling light-headed or dizziness fever fainting weakness flushing diarrhea rash nausea and vomiting sweating Tell your doctor right away if you have: a fever over 100 F shaking or chills that continue or get worse a painful lump or swelling (because this may be a sign of a blood clot) bruising that is increasing in diameter (because this may be a sign of a clotting problem) oddly colored urine trouble urinating severe back pain severe abdominal pain swelling, especially around the ankles hives shortness of breath Talk to your doctor about any side effects that concern you. Additional prescribing information is available to healthcare professionals. 5. What other information do I need to know about WinRho SDF? WinRho SDF is made from human plasma. Donors are carefully screened and the plasma is carefully cleaned, but it does have a very small risk of giving you viruses from the donor. Talk to your doctor if you have any symptoms that concern you. You may report side effects to Cangene Corporation at or FDA s MedWatch reporting system by phone (1-800-FDA-1088). ITP Support Platelet Disorder Support Association Phone: 1-87-PLATELET ( ) or pdsa@pdsa.org Website: 20 Please see full Prescribing Information at
12 Summary of 4 studies of WinRho SDF in a range of children and adults. 1 Childhood Chronic ITP In an open-label, single arm, multicenter study, 24 non-splenectomized, Rho(D)-positive children with ITP of greater than six months duration were treated initially with 250 international unit/kg (50 mcg/kg) WinRho SDF [125 international unit/kg (25 mcg/kg) on days 1 and 2, with subsequent doses ranging from 125 to 275 international unit/kg (25 to 55 mcg/kg)]. Response was defined as a platelet increase to at least 50,000/mm 3 and a doubling of the baseline. Nineteen of 24 patients responded for an overall response rate of 79%, an overall mean peak platelet count of 229,400/mm 3 (range 43,300 to 456,000), and a mean duration of response of 36.5 days (range 6 to 84). Childhood Acute ITP A multicenter, randomized, controlled trial comparing WinRho SDF to high dose and low dose Immune Globulin Intravenous (Human) (IGIV) and prednisone was conducted in 146 non-splenectomized, Rho(D)-positive children with acute ITP and platelet counts less than 20,000/mm 3. Of 38 patients receiving WinRho SDF [125 international unit/kg (25 mcg/kg) on days 1 and 2], 32 patients (84%) responded (platelet count 50,000/mm 3 ) with a mean peak platelet count of 319,500/mm 3 (range 61,000 to 892,000), with no statistically significant differences compared to other treatment arms. The mean times to achieving 20,000/mm 3 or 50,000/mm 3 platelets for patients receiving WinRho SDF were 1.9 and 2.8 days respectively. When comparing the different therapies for time to platelet count 20,000/mm 3 or 50,000/mm 3, no statistically significant differences among treatment groups were detected, with a range of 1.3 to 1.9 days and 2.0 to 3.2 days, for IGIV and prednisone respectively. Adult Chronic ITP Twenty-four non-splenectomized Rho(D)-positive adults with ITP of greater than six months duration and platelet counts <30,000/mm 3 or requiring therapy enrolled in a single-arm, open-label trial were treated with 100 to 375 international unit/kg (20 to 75 mcg/kg) WinRho SDF [mean dose 231 international unit/kg (46.2 mcg/kg)]. Twenty-one of 24 patients responded (increase 20,000/mm 3 ) during the first two courses of therapy for an overall response rate of 88% with a mean peak platelet count of 92,300/mm 3 (range 8,000 to 229,000). ITP Secondary to HIV Infection Eleven children and 52 adults, who were non-splenectomized and Rho(D)-positive, with all Walter Reed classes of HIV infection and ITP, with initial platelet counts of 30,000/mm 3 or requiring therapy, were treated with 100 to 375 international unit/kg (20 to 75 mcg/kg) WinRho SDF in an open label trial. WinRho SDF was administered for an average of 7.3 courses (range 1 to 57) over a mean period of 407 days (range 6 to 1,952). Fifty-seven of 63 patients responded (increase 220,000/mm 3 ) during the first six courses of therapy for an overall response rate of 90%. The overall mean change in platelet count for six courses was 60,900/mm 3 (range 2,000 to 565,000), and the mean peak platelet count was 81,700/mm 3 (range 16,000 to 593,000). References: 1. WinRho SDF Prescribing Information: Baltimore, MD: Cangene biopharma, Inc; December Mayo Clinic website. Disease and conditions: Idiopathic thrombocytopenic purpura (ITP). Accessed on October 1, Data on file. Berwyn, PA, Emergent BioSolutions. 4. Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16): Manufactured by Cangene Corporation and distributed by Cangene biopharma, Inc. WinRho SDF and any and all Emergent BioSolutions Inc. brand, product, service and feature names, logos and slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries Emergent BioSolutions Inc. All rights reserved. XXXXXXXX Phone: WINRHO ( )
For platelet control as individual as you
For platelet control as individual as you Explore the possibilities of Immune Thrombocytopenic Purpura (ITP) treatment. Important Risk Information WARNING: INTRAVASCULAR HEMOLYSIS (IVH) Intravascular hemolysis
More informationWhat You Need to Know About LEMTRADA (alemtuzumab) Treatment: A Patient Guide
For Patients What You Need to Know About LEMTRADA (alemtuzumab) Treatment: A Patient Guide Patients: Your doctor or nurse will go over this patient guide with you. It is important to ask any questions
More informationUse of Intravenous Anti-RhD Immunoglobulin (RhIG) in the Treatment of Primary Immune Thrombocytopenia
Use of Intravenous Anti-RhD Immunoglobulin (RhIG) in the Treatment of Primary Immune Thrombocytopenia KRISTINA WILLIAMS ABSTRACT Commercialized intravenous immunoglobulin (IVIG) products have been used
More informationA Patient s Guide to Blood Components and Products
2014 A Patient s Guide to Blood Components and Products Contents What is a blood transfusion?... 1 Informed consent... 1 Frequently asked questions about blood transfusions... 2 What can I expect during
More informationHave a healthy discussion. Use this guide to start a. conversation. with your. healthcare provider
Have a healthy discussion Use this guide to start a conversation with your healthcare provider MAKE THE CONVERSATION COUNT Here are some things you may want to reflect on and discuss with your healthcare
More informationContemporary perspectives and initial management of pediatric ITP. William Beau Mitchell, MD Weill Cornell Medical College New York, NY USA
Contemporary perspectives and initial management of pediatric ITP William Beau Mitchell, MD Weill Cornell Medical College New York, NY USA Case Presentation 5 year old female Bruises on trunk, extremities
More informationQUICK REFERENCE Clinical Practice Guideline on the Evaluation and Management of Immune Thrombocytopenia (ITP)
QUICK REFERENCE 2011 Clinical Practice Guideline on the Evaluation and Management of Immune Thrombocytopenia (ITP) Presented by the American Society of Hematology, adapted from: The American Society of
More informationIVIg. Treatment With Privigen. Proven protection Designed for stability. Your guide to USED IN US HOSPITALS SINCE 2010
# 1 IVIg USED IN US HOSPITALS SINCE 2010 Your guide to Treatment With Privigen For people with primary immunodeficiency (PI) Proven protection Designed for stability Please see full Important Safety Information
More informationSTEP-BY-STEP GUIDE TO SELF-INFUSION. Subcutaneous Administration of GAMMAGARD LIQUID
STEP-BY-STEP GUIDE TO SELF-INFUSION Subcutaneous Administration of GAMMAGARD LIQUID This handy guide will help you manage your subcutaneous administration of GAMMAGARD LIQUID. If you have questions on
More informationPRESCRIBER SAFETY BROCHURE; IMPORTANT SAFETY INFORMATION FOR THE HEALTHCARE PROVIDER
PRESCRIBER SAFETY BROCHURE; IMPORTANT SAFETY INFORMATION FOR THE HEALTHCARE PROVIDER BEFORE STARTING YOUR PATIENTS ON SOLIRIS Important safety information for the healthcare provider Prior to initiating
More informationAcute Immune Thrombocytopenic Purpura (ITP) in Childhood
Acute Immune Thrombocytopenic Purpura (ITP) in Childhood Guideline developed by Robert Saylors, MD, in collaboration with the ANGELS team. Last reviewed by Robert Saylors, MD September 22, 2016. Key Points
More informationWARNING: SERIOUS MENINGOCOCCAL INFECTIONS
Indication and Usage Paroxysmal Nocturnal Hemoglobinuria (PNH) Soliris (eculizumab) is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. WARNING:
More informationIF YOU HAVE PNH, YOU ARE NOT ALONE. Take a closer look and take control of PNH
IF YOU HAVE PNH, YOU ARE NOT ALONE Take a closer look and take control of PNH Indication and Usage Paroxysmal Nocturnal Hemoglobinuria (PNH) Soliris (eculizumab) is indicated for the treatment of patients
More informationPATIENT SAFETY BROCHURE; IMPORTANT SAFETY INFORMATION FOR PATIENTS. Before starting on Soliris Important safety information for patients
PATIENT SAFETY BROCHURE; IMPORTANT SAFETY INFORMATION FOR PATIENTS Before starting on Soliris Important safety information for patients Before you begin Soliris (eculizumab) treatment, your physician will
More informationCONSUMER MEDICINE INFORMATION (CMI) OCTAGAM 10% [100 mg/ml]
CONSUMER MEDICINE INFORMATION (CMI) OCTAGAM 10% [100 mg/ml] Human Normal Immunoglobulin Solution for Intravenous Infusion. OCTAGAM 10% [100 mg/ml] is available in single use bottles of 20 ml, 50 ml, 100
More information1 Ig. Prescribed for PI
1 Ig # Prescribed for PI Hizentra is a prescription medicine used to treat primary immune deficiency (PI) in patients 2 years and older. *Ig=Immunoglobulin Please see full on pages 12 13 and full prescribing
More informationBefore starting on Soliris.
Before starting on Soliris. Important safety information for patients Before you begin Soliris (eculizumab) treatment, your physician will give you a: Medication Guide Soliris Patient Safety Information
More informationThe ITP Patient Advocate
The ITP Patient Advocate A Resource for Your Journey With Chronic ITP Visit nplate.com for more information Issue Two Medical News About Nplate This issue looks at a recent 1-year Nplate medical study
More informationFULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WinRho SDF safely and effectively. See full prescribing information for WinRho SDF. WinRho SDF [Rh
More informationDexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop.
Dexamethasone Other Names: Decadron About This Drug Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop. Possible Side Effects (More Common) Increased
More informationeltrombopag (Promacta )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationTransfusion Reactions. Directed by M-azad March 2012
Transfusion Reactions Directed by M-azad March 2012 Transfusion Reactions are Adverse reactions associated with the transfusion of blood and its components Transfusion reactions Non-threatening to fatal
More informationFor the Patient: Rituximab injection Other names: RITUXAN
For the Patient: Rituximab injection Other names: RITUXAN Rituximab (ri tux' i mab) is a drug that is used to treat some types of cancer. It is a monoclonal antibody, a type of protein designed to target
More informationWhat is the most important information I should know about bortezomib? What should I discuss with my healthcare provider before receiving bortezomib?
1 of 5 6/10/2016 3:46 PM Generic Name: bortezomib (bor TEZ oh mib) Brand Name: Velcade What is bortezomib? Bortezomib interferes with the growth of some cancer cells and keeps them from spreading in your
More informationA treatment to fit your needs
A treatment to fit your needs Aranesp (darbepoetin alfa) is a prescription medicine used to treat a lower than normal number of red blood cells (anemia) caused by chronic kidney disease in patients on
More informationOpen to the possibility of a multiple myeloma treatment that works in cells in your body at the DNA level
If you have multiple myeloma and have already tried at least 2 other types of treatment Open to the possibility of a multiple myeloma treatment that works in cells in your body at the DNA level What is
More informationMEDICATION GUIDE. (tocilizumab)
MEDICATION GUIDE ACTEMRA (AC-TEM-RA) (tocilizumab) Read this Medication Guide before you start ACTEMRA and before each infusion. There may be new information. This Medication Guide does not take the place
More informationBlood Transfusion Orientation & Information 2010
Blood Transfusion Orientation & Information 2010 *if you are able to get online for this training: http://www.nhlbi.nih.gov/health/dci/diseases/bt/bt_whatis.html and you can read all information included
More informationWhat should I discuss with my health care provider before taking eltrombopag?
1 of 6 6/10/2016 3:57 PM Generic Name: eltrombopag (el TROM boe pag) Brand Name: Promacta What is eltrombopag? Eltrombopag is a man-made form of a protein that increases production of platelets (blood-clotting
More informationDaunorubicin daw-no-roo-bih-sin
Patient Education daw-no-roo-bih-sin This medicine, like all medicines used to treat cancer, is very strong. Make sure you understand why you are getting it and what the risks and benefits of treatment
More informationTalking about your treatment. A guide to the conversations you may have before starting LEMTRADA
Talking about your treatment A guide to the conversations you may have before starting LEMTRADA INTRODUCTION HEALTHCARE TEAM CARE TEAM COWORKERS Please see Important Safety Information on pages 6-7 and
More informationWhat should I ask my treatment team?
TREATMENT TRANSFORMED Child portrayed is not a real KYMRIAH patient. DISCUSSION GUIDE What should I ask my treatment team? Making treatment decisions for relapsed or refractory cancer can be hard. Asking
More informationNivolumab. Other Names: Opdivo. About this Drug. Possible Side Effects (More Common) Warnings and Precautions
Nivolumab Other Names: Opdivo About this Drug Nivolumab is used to treat cancer. It is given in the vein (IV). Possible Side Effects (More Common) Bone marrow depression. This is a decrease in the number
More informationQUESTIONS TO ASK MY DOCTOR
Be a part of the treatment decision by asking questions QUESTIONS TO ASK MY DOCTOR FOR PATIENTS WITH ADVANCED STOMACH OR GASTROESOPHAGEAL JUNCTION (GEJ) CANCER CYRAMZA (ramucirumab) is used alone or in
More informationWhat do I need to tell my doctor BEFORE I take this drug?
PATIENT & CAREGIVER EDUCATION Antithymocyte Globulin (Equine) Brand Names: US Atgam Brand Names: Canada Atgam Warning Unsafe allerg ic effects may happen. You will be closely watched by your doctor. What
More informationTRANSFUSION REACTION EVALUATION
Lab Dept: Test Name: Transfusion Services TRANSFUSION REACTION EVALUATION General Information Lab Order Codes: Synonyms: CPT Codes: Test Includes: TRXR Transfusion Complication Workup; Hemolytic reaction
More informationWhat You Need to Know About ARZERRA (ofatumumab)
Starting your treatment for chronic lymphocytic leukemia (CLL) What You Need to Know About ARZERRA (ofatumumab) Approved Use ARZERRA is a prescription medication used: With a chemotherapy drug called chlorambucil
More informationA Guide for Patients and Caregivers
DLBCL Starting KYMRIAH A Guide for Patients and Caregivers APPROVED USE WHAT IS KYMRIAH? KYMRIAH (tisagenlecleucel) is made from your own white blood cells and is a prescription cancer treatment used in
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION BAVENCIO (buh-ven-see-oh) Avelumab for Injection Solution for Intravenous Infusion, 20 mg/ml Professed Standard Antineoplastic
More informationLEMTRADA REMS Education Program for Healthcare Facilities
For Healthcare Facilities LEMTRADA REMS Education Program for Healthcare Facilities This Educational Piece Includes Information About: The LEMTRADA REMS Program requirements to implement in your healthcare
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION BAVENCIO (buh-ven-see-oh) Avelumab for Injection Solution for Intravenous Infusion Read this carefully before you start
More informationBefore you are given Privigen
Normal immunoglobulin (Human) 10% (100 g/l), intravenous injection. Consumer Medicine Information What is in this leaflet This leaflet contains answers to some common questions about. It does not contain
More informationwas proven to help people live longer1 BLINCYTO A guide for patients and caregivers
In a clinical trial for people with a certain kind of ALL whose cancer has returned or didn t respond to treatment 1 BLINCYTO was proven to help people live longer1 In a study of 405 adults with ALL, 271
More informationTreatment Journal. Therapy Tracker TREATMENT JOURNAL
TREATMENT JOURNAL Treatment Journal & Therapy Tracker Please see full Prescribing Information, including Boxed WARNING and Medication Guide, for FARYDAK (panobinostat) capsules. This journal can help you:
More informationKeeping track of your numbers
Keeping track of your numbers If you have relapsed or refractory multiple myeloma, keeping track of your numbers can help you take an active role in your care. It s also one way you and your doctor can
More informationImportant safety information to minimise the risk of immune-related adverse reactions
Your Guide to KEYTRUDA (pembrolizumab) Important safety information to minimise the risk of immune-related adverse reactions Information for Patients This medicine is subject to additional monitoring.
More informationBlood Transfusion. There are three types of blood cells: Red blood cells. White blood cells. Platelets.
Blood Transfusion Introduction Blood transfusions can save lives. Every second, someone in the world needs a blood transfusion. Blood transfusions can replace the blood lost from a serious injury or surgery.
More informationNURSING PROCESS FOCUS: Patients Receiving Amphotericin B (Fungizone, Abelcet)
NURSING PROCESS FOCUS: Patients Receiving Amphotericin B (Fungizone, Abelcet) ASSESSMENT Prior to administration: Obtain complete health history including allergies, drug history, and possible drug interactions.
More informationImmune Thrombocytopenic Purpura (ITP)
Patient information Immune Thrombocytopenic Purpura Immune Thrombocytopenic Purpura (ITP) This leaflet is for adult patients diagnosed with Immune Thrombocytopenic Purpura also known as Immune Thrombocytopenia
More informationTREPROSTINIL INJECTION
TREPROSTINIL INJECTION FOR PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) Indication Treprostinil Injection is a prescription medication used in adults with pulmonary arterial hypertension (PAH), World
More informationBLINCYTO can eliminate detectable traces of cancer 1
For people* with B-cell precursor ALL who are MRD+, 1 BLINCYTO can eliminate detectable traces of cancer 1 In a study of 86 adults with MRD+ B-cell precursor ALL, BLINCYTO removed detectable traces of
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Romiplostim Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 12/15/2017 Next
More informationINVESTIGATION OF ADVERSE TRANSFUSION REACTIONS TABLE OF RECOMMENDED TESTS. Type of Reaction Presentation Recommended Tests Follow-up Tests
Minor Allergic (Urticarial) Urticaria, pruritis, flushing, rash If skin reaction only and mild hives/ rash
More informationStarting KAZANO gave me MORE POWER than metformin alone, with 2 medicines in 1 tablet
For many adults with type 2 diabetes Starting KAZANO gave me MORE POWER than metformin alone, with 2 medicines in 1 tablet Individual results may vary. Not actual patient. KAZANO is a prescription medicine
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION WINRHO SDF
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION WINRHO SDF Rh o (D) Immune Globulin (Human) for Injection Single-Dose Vials: 600 IU (120 µg) 1500 IU (300 µg) 2500 IU (500 µg) 5000 IU (1000 µg)
More informationDoes yours? Most school-age kids with asthma have allergic asthma. Enroll in our support program. Learn about this distinct condition
Most school-age kids with asthma have allergic asthma. Does yours? Learn about this distinct condition Enroll in our support program for tools, information on financial resources, and more at GetSupportForYou.com
More informationPatient Information IXEMPRA Kit (pronounced as ǐk-'sĕm-pră) (ixabepilone) What is the most important information I should know about IXEMPRA?
17.6 FDA-Approved Patient Labeling Patient Information IXEMPRA Kit (pronounced as ǐk-'sĕm-pră) (ixabepilone) for Injection, for intravenous infusion only Read the Patient Information that comes with IXEMPRA
More informationThe Role of Anti-D in the Management of Chronic and Secondary Forms of ITP
The Role of Anti-D in the Management of Chronic and Secondary Forms of ITP 473 82 The Role of Anti-D in the Management of Chronic and Secondary Forms of ITP MAURICE GILLES GENEREUX BACKGROUND Immune thrombocytopenic
More informationMEDICATION GUIDE. Epogen (Ee-po-jen) (epoetin alfa)
MEDICATION GUIDE Epogen (Ee-po-jen) (epoetin alfa) Read this Medication Guide before you start Epogen, each time you refill your prescription, and if you are told by your healthcare provider that there
More informationRituximab FOR NEUROLOGICAL DISORDERS
InfoNeuro Montreal Neurological Institute and Hospital INFORMATION FOR PATIENTS Rituximab FOR NEUROLOGICAL DISORDERS Prepared by: Sylvia de Melo, Nurse Clinician, Neuro Day Center Consultants: Lucia Fabijan,
More informationFuel your determination to live longer with KYPROLIS. Look inside to learn more.
F O R R E L A P S E D MULT IP L E M Y E L OM A APPROVED USES KYPROLIS is a prescription medication used to treat patients with relapsed or refractory multiple myeloma who have received one to three previous
More informationQUESTIONS TO ASK MY DOCTOR
Be a part of the treatment decision by asking questions QUESTIONS TO ASK MY DOCTOR FOR PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER CYRAMZA (ramucirumab) is used with a chemotherapy called docetaxel
More informationLIVE LONGER. Chart a course that could help you. If multiple myeloma comes back:
1 If multiple myeloma comes back: Chart a course that could help you 1 LIVE LONGER -3 In two clinical studies with patients with relapsed multiple myeloma, two KYPROLIS -based combinations kept multiple
More informationoffers the possibility of a longer life 1 BLINCYTO A guide for patients and caregivers
In a study of 405 adults with Philadelphia chromosome negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia, 271 were treated with BLINCYTO and 134 with chemotherapy. The adults
More informationMEDICATION GUIDE Prasugrel (pra-su-grel) tablets Read this Medication Guide before you start taking prasugrel and each time you get a refill.
MEDICATION GUIDE Prasugrel (pra-su-grel) tablets Read this Medication Guide before you start taking prasugrel and each time you get a refill. There may be new information. This Medication Guide does not
More informationDo not g ive this drug if your child has an infection or any inflammation.
PATIENT & CAREGIVER EDUCATION Tisagenlecleucel Brand Names: US Kymriah Warning A very bad health problem called cytokine release syndrome (CRS) has happened with this drug. Sometimes, this has been life-threatening
More informationPRODUCT MONOGRAPH WINRHO SDF
PRODUCT MONOGRAPH WINRHO SDF Rh o (D) Immune Globulin (Human) for injection Lyophilized: 600 IU (120 µg), 1500 IU (300 µg), 5000 IU (1000 µg) Liquid: 600 IU (120 µg), 1500 IU (300 µg), 2500 IU (500 µg),
More informationHighlights from the IG Living Teleconference, April 5, 2017
Highlights from the IG Living Teleconference, April 5, 2017 Topic: Treating IG Side Effects [This is an edited version of a live teleconference presentation.] Guest Speaker: Mark Riedl, MD, MS, board-certified
More informationGAZYVA for Chronic Lymphocytic Leukemia (CLL)
GAZYVA for Chronic Lymphocytic Leukemia (CLL) GAZYVA is a prescription medicine used with the chemotherapy drug, chlorambucil, to treat chronic lymphocytic leukemia (CLL) in adults who have not had previous
More informationDiscussing TECENTRIQ (atezolizumab) with your healthcare team Talking to Your Doctor
Discussing TECENTRIQ (atezolizumab) with your healthcare team Talking to Your Doctor TECENTRIQ DISCUSSION SUPPORT What is TECENTRIQ? TECENTRIQ is a prescription medicine used to treat: A type of bladder
More informationMost Common Hemostasis Consults: Thrombocytopenia
Most Common Hemostasis Consults: Thrombocytopenia Cindy Neunert, MS MSCS Assistant Professor, Pediatrics CUMC Columbia University TSHNA Meeting, April 15, 2016 Financial Disclosures No relevant financial
More informationGetting started with PROMACTA (eltrombopag)
Getting started with PROMACTA (eltrombopag) Indications PROMACTA is a prescription medicine used to treat adults and children 1 year and older with low blood platelet counts due to chronic immune (idiopathic)
More informationNephrotic Syndrome (Childhood Nephrosis)
Nephrotic Syndrome (Childhood Nephrosis) This handout has been written to help you learn about nephrotic syndrome and how to take care of your child at home. If you have any questions, please be sure to
More informationPRODUCT MONOGRAPH. obinutuzumab. 25 mg/ml Concentrate for Solution for Infusion. Professed Standard. Antineoplastic
PRODUCT MONOGRAPH Pr GAZYVA obinutuzumab 25 mg/ml Concentrate for Solution for Infusion Professed Standard Antineoplastic Hoffmann-La Roche Limited 7070 Mississauga Rd. Mississauga, Ontario, Canada L5N
More informationFOR PATIENTS WITH SYMPTOMS OF SARCOIDOSIS. Treatment Journal. H.P. Acthar Gel is a prescription medication used to treat symptoms of sarcoidosis.
FOR PATIENTS WITH SYMPTOMS OF SARCOIDOSIS Treatment Journal H.P. Acthar Gel is a prescription medication used to treat symptoms of sarcoidosis. IMPORTANT SAFETY INFORMATION Who should NOT take Acthar?
More informationHow does my new treatment work?
How does my new treatment work? Get to know KEVZARA better. Click here for full Prescribing Information including 1 risk of SERIOUS SIDE EFFECTS and Medication Guide. You're starting KEVZARA... GOT A QUESTION?
More informationX-Plain Blood Transfusion Reference Summary
X-Plain Blood Transfusion Reference Summary Introduction Blood transfusions are very common. Each year, almost 5 million Americans need a blood transfusion. Blood transfusions are given to replace blood
More informationMEDICATION GUIDE. BENLYSTA (ben-list-ah) (belimumab) Injection for intravenous use
MEDICATION GUIDE BENLYSTA (ben-list-ah) (belimumab) Injection for intravenous use Read this Medication Guide before you start receiving BENLYSTA and before each treatment. There may be new information.
More information2013 National Treatment Survey. Immune Deficiency Foundation
2013 National Treatment Survey Immune Deficiency Foundation IDF 2013 Treatment Survey Mail-based, pencil & paper survey Over 75 Main questions Survey in the field December 2013-March 2014 IDF mail invitation
More informationFor the Patient: Bendamustine Other names: TREANDA
For the Patient: Bendamustine Other names: TREANDA Bendamustine (ben'' da mus' teen) is a drug that is used to treat some types of cancer (lymphoma). It is a clear liquid that is injected into a vein.
More informationORENCIA (oh-ren-see-ah) (abatacept)
17.7 FDA-Approved Patient Labeling PATIENT INFORMATION ORENCIA (oh-ren-see-ah) (abatacept) Read this Patient Information before you start receiving ORENCIA and each time before you are scheduled to receive
More informationThere s. to you THAT S WHY THERE S MORE TO GAMUNEX-C. *Chronic inflammatory demyelinating polyneuropathy.
There s more to you THAT S WHY THERE S MORE TO GAMUNEX-C YOUR GUIDE FOR THE LONG-TERM TREATMENT OF CIDP * *Chronic inflammatory demyelinating polyneuropathy. Please see Important Safety Information on
More informationSoliris (eculizumab) For the Treatment of PNH to Reduce Hemolysis
Soliris (eculizumab) You have done well to manage your PNH with Soliris. Living with a rare disease, like PNH, can be challenging, but by sticking with your Soliris therapy, you are doing a lot to help
More informationREADY. SET. DOPTELET. HELP GET READY FOR YOUR UPCOMING PROCEDURE
HELP GET READY FOR YOUR UPCOMING PROCEDURE READY. SET. DOPTELET. Full Prescribing Information for DOPTELET (avatrombopag), including Patient For adults with chronic liver disease and a low platelet count
More informationThe Child with a Hematologic Alteration
47 The Child with a Hematologic Alteration HELPFUL HINT Review the anatomy and physiology of the hematologic system in an anatomy and physiology textbook. MATCHING KEY TERMS Match the term with the correct
More informationActhar TREATMENT JOURNAL
Acthar TREATMENT JOURNAL Help for patients in the grip of dermatomyositis or polymyositis What is Acthar? Acthar is a prescription medicine used for flares or on a regular basis (maintenance) in people
More informationGemcitabine and Cisplatin
PATIENT EDUCATION patienteducation.osumc.edu What is Gemcitabine (jem-site-a been)? Gemcitabine is a chemotherapy medicine known as an anti-metabolite. Another name for this drug is Gemzar. This drug is
More informationBlood Transfusion Reactions
Blood Transfusion Reactions Introduction Many individuals require blood components and blood products. As per the BC Transfusion Medicine Advisory Group (BCTMAG), a blood component is at therapeutic component
More informationONE PILL, ONCE A DAY GET TO KNOW AUBAGIO. Ask your doctor if AUBAGIO may be right for you. Patient Portrayal
ONE PILL, ONCE A DAY GET TO KNOW AUBAGIO Patient Portrayal Ask your doctor if AUBAGIO may be right for you. INDICATION AUBAGIO (teriflunomide) is a prescription medicine used to treat relapsing forms of
More informationTuscarawas County Health Department. Vivitrol Treatment Consent
Tuscarawas County Health Department Vivitrol Treatment Consent I. Vivitrol Medication Guide: a. VIVITROL (viv-i-trol) (naltrexone for extended-release injectable suspension) b. Read this Medication Guide
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. SYLVANT pronounced SILL-vant siltuximab for injection
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr SYLVANT pronounced SILL-vant siltuximab for injection Read this carefully before you start taking SYLVANT and each
More informationPATIENT AUTHORIZATION AND NOTICE OF RELEASE OF INFORMATION (PAN)
XOLAIR Access Solutions is a free program for you from Genentech. We work to help you pay for your XOLAIR (omalizumab) for subcutaneous use. We can help in many different ways. We assist people who have
More informationThere are two main causes of a low platelet count
Thrombocytopenia Thrombocytopenia is a condition in which a person's blood has an unusually low level of platelets Platelets, also called thrombocytes, are found in a person's blood along with red blood
More informationHow are unresolved Myasthenia Gravis symptoms disrupting your day? Talk to your doctor about your symptoms
How are unresolved Myasthenia Gravis symptoms disrupting your day? Talk to your doctor about your symptoms Recognize the symptoms of your generalized Myasthenia Gravis (gmg) Anti-acetylcholine receptor
More informationNormal Immunoglobulin (Human) 16%, solution for subcutaneous administration.
Normal Immunoglobulin (Human) 16%, solution for subcutaneous administration. Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about. It does not contain
More information2/2/2011. Blood Components and Transfusions. Why Blood Transfusion?
Blood Components and Transfusions Describe blood components Identify nursing responsibilities r/t blood transfusion Discuss factors r/t blood transfusion including blood typing, Rh factor, and cross matching
More informationDeveloped by Stephanie Zachary, Sarah Weicker, Dr. Jeremy Friedman, Dr. Carolyn Beck, and Dr. Lauren Kitney for PedsCases.com.
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on Primary Immune Thrombocytopenia (ITP) CPS Podcast These podcasts are designed to give medical students an overview of
More informationUNDERSTANDING MYELOFIBROSIS (MF) A guide for patients and caregivers
UNDERSTANDING MYELOFIBROSIS (MF) A guide for patients and caregivers Jakafi is used to treat adults with intermediate or high-risk myelofibrosis (MF), including primary MF, post polycythemia vera MF and
More informationThe ORENCIA (abatacept) JIA Observational Registry
Moderate to Severe Juvenile Idiopathic Arthritis (JIA) Injection for Intravenous Use Injection for Subcutaneous Use The ORENCIA (abatacept) JIA Observational Registry Injection for Intravenous Use Injection
More information